Evogene (EVGN) chief development officer reports 40,000-share stock option grant

Rhea-AI Filing Summary

Evogene Ltd. Chief Development Officer Gabi Tarcic filed an initial ownership report showing a stock option position. The option gives the right to buy 40,000 ordinary shares at an exercise price of $2.305 per share and expires on November 20, 2034.

According to the vesting terms, 25% of the options vest on the first anniversary of the November 20, 2024 grant date. The remaining options vest in equal quarterly installments of 6.25% over the next twelve quarters, so all options are fully vested four years after the grant date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Tarcic Gabi

Role Chief Development Officer

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy ordinary shares)	--	--	--

Holdings After Transaction: Stock Option (right to buy ordinary shares) — 40,000 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Tarcic Gabi

(Last) (First) (Middle)

6 HASHIKMA ST.

(Street)

MEVASERET ZION 9071603

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Evogene Ltd. [ EVGN ]

3a. Foreign Trading Symbol
[EVGN]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy ordinary shares)	(1)	11/20/2034	Ordinary shares	40,000	$2.305	D

Explanation of Responses:

1. The options reported in this row vest over a period of four years, with 25% vesting upon the first anniversary of the November 20, 2024 grant date, and the remainder vesting on an equal quarterly basis (6.25% per quarter) over the following twelve quarters, such that all options will be fully vested on the four-year anniversary of the November 20, 2024 grant date.

Remarks:

Exhibit 24.1 - Power of Attorney.

	/s/ Nitsan Deutsch, attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Evogene (EVGN) Chief Development Officer report on this Form 3?

The filing shows Chief Development Officer Gabi Tarcic’s initial ownership of a stock option. The option covers 40,000 Evogene ordinary shares at a $2.305 exercise price, expiring November 20, 2034, with a four-year vesting schedule starting November 20, 2024.

How many Evogene (EVGN) shares are covered by Gabi Tarcic’s stock option?

The reported stock option gives the right to buy 40,000 Evogene ordinary shares. This is a derivative position, not currently owned common stock, and it becomes exercisable gradually as the option vests over the four-year period following the November 20, 2024 grant date.

What is the exercise price of the Evogene (EVGN) stock option reported?

The stock option held by Chief Development Officer Gabi Tarcic has an exercise price of $2.305 per ordinary share. This means shares can be purchased at $2.305 once portions of the option become vested and remain exercisable until the November 20, 2034 expiration date.

How do the Evogene (EVGN) options reported by Gabi Tarcic vest over time?

The options vest over four years. Twenty-five percent vest on the first anniversary of the November 20, 2024 grant date. The remaining 75% vest in equal 6.25% quarterly installments across the next twelve quarters, so all options are fully vested four years after the grant.

When do the stock options reported by Evogene (EVGN) executive Gabi Tarcic expire?

The stock option position expires on November 20, 2034. After that date, any unexercised portion can no longer be used to purchase Evogene ordinary shares, making the vesting and exercise period effectively ten years from the original November 20, 2024 grant date.

Is the Evogene (EVGN) Form 3 a record of a stock purchase or sale?

No, this Form 3 is an initial ownership report showing a stock option holding, not a share purchase or sale. It discloses a right to buy 40,000 ordinary shares at $2.305, subject to a four-year vesting schedule and a November 20, 2034 expiration date.